Financial Performance - The company's revenue for Q1 2022 was ¥250,022,104.21, representing a 38.59% increase compared to ¥180,406,859.36 in the same period last year[3] - Net profit attributable to shareholders was ¥12,478,199.47, up 68.84% from ¥7,390,662.30 year-on-year[3] - Basic earnings per share rose to ¥0.0597, a 61.35% increase from ¥0.0370 in the same period last year[3] - Total operating revenue for the first quarter was CNY 250,022,104.21, an increase of 38.6% compared to CNY 180,406,859.36 in the previous period[22] - Net profit for the period reached CNY 10,909,591.98, representing a 46.4% increase from CNY 7,468,842.31 in the same period last year[23] - The total comprehensive income for the period was CNY 10,876,464.25, compared to CNY 7,482,374.73 in the previous period, representing an increase of approximately 45.5%[24] Cash Flow - The net cash flow from operating activities increased by 287.74% to ¥68,005,318.04, compared to ¥17,538,692.11 in the previous year[9] - The net cash flow from operating activities was CNY 68,005,318.04, significantly up from CNY 17,538,692.11 in the previous period, indicating a growth of about 287.5%[27] - The net cash flow from investing activities was -CNY 18,224,541.24, worsening from -CNY 8,339,974.85 in the previous period[27] - The net cash flow from financing activities surged by 759.14% to ¥37,672,157.22, compared to -¥5,715,313.80 in the previous year[9] - The net cash flow from financing activities was CNY 37,672,157.22, compared to -CNY 5,715,313.80 in the previous period, indicating a turnaround[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,541,440,427.35, a 2.31% increase from ¥1,506,596,737.33 at the end of the previous year[3] - The total assets of the company increased to CNY 1,541,440,427.35 from CNY 1,506,596,737.33, a growth of 2.3%[21] - The total liabilities decreased slightly to CNY 705,709,569.01 from CNY 710,032,521.28, a decline of 0.3%[21] - The company’s total liabilities decreased by 40.93% in employee compensation payable, from ¥39,256,120.61 to ¥23,189,384.18[7] Research and Development - The company reported a 33.42% increase in R&D expenses, totaling ¥5,459,065.78 compared to ¥4,091,776.07 in the previous year[8] - Research and development expenses increased to CNY 5,459,065.78 from CNY 4,091,776.07, a rise of 33.5%[23] Shareholder Activities - The controlling shareholder and actual controller, Cao Deli, along with his concerted actors, have cumulatively increased their holdings by 7,805,983 shares, accounting for 3.73% of the total share capital, which is 86.73% of the lower limit of their planned increase of 9 million shares[14] - The company has extended the deadline for the shareholding increase plan from February 8, 2022, to August 8, 2022[14] - The stock option incentive plan allows 19 eligible participants to exercise 7,378,000 stock options at a price of 14.19 yuan per share, starting from February 24, 2022[16] - As of the report date, 916,855 stock options have been exercised in the first exercise period, while none have been exercised in the second period[16] Inventory and Borrowings - Inventory decreased to CNY 184,164,228.41 from CNY 238,289,008.96, a reduction of 22.7%[20] - Short-term borrowings rose to CNY 281,909,484.66 from CNY 238,964,254.96, an increase of 17.9%[20] Other Financial Metrics - The weighted average return on equity increased by 0.42 percentage points to 1.57% from 1.15% year-on-year[3] - The company's equity attributable to shareholders rose to CNY 811,288,513.50 from CNY 770,553,263.72, an increase of 5.3%[21] - The company's cash and cash equivalents increased to CNY 248,379,733.65 from CNY 131,906,431.44 at the beginning of the year, reflecting a growth of 88.1%[20] - The cash and cash equivalents at the end of the period totaled CNY 218,379,733.65, up from CNY 114,993,577.66 in the previous period, an increase of approximately 90.0%[27] Audit Information - The company did not conduct an audit for the first quarter report[28]

Financial Performance - The company's revenue for Q3 2021 reached ¥294,847,063.85, representing an increase of 86.43% compared to the same period last year[3] - Net profit attributable to shareholders was ¥1,549,625.93, a decrease of 75.37% year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥1,232,219.65, down 79.45% from the previous year[3] - Total operating revenue for the third quarter reached ¥719,415,783.64, a significant increase from the previous period's revenue of ¥462,392,212.54[21] - The net profit for Q3 2021 was CNY 27,284,046.62, a decrease of 24.1% compared to CNY 35,975,928.62 in Q3 2020[23] - Operating profit for Q3 2021 was CNY 42,287,355.99, down from CNY 48,626,612.87 in the same period last year, reflecting a decline of 13.7%[23] - The company experienced a total profit of CNY 42,225,666.83 in Q3 2021, which is a decrease of 12.5% from CNY 48,273,639.49 in Q3 2020[23] - The total comprehensive income attributable to the parent company for Q3 2021 was CNY 27,069,491.56, compared to CNY 35,938,457.39 in Q3 2020, a decrease of 24.4%[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,336,829,712.11, an increase of 12.72% compared to the end of the previous year[4] - Current liabilities totaled ¥489,816,133.43, an increase from ¥458,449,238.26, indicating a rise in short-term financial obligations[19] - The total equity attributable to shareholders rose to ¥714,719,370.08 from ¥639,140,711.44, demonstrating improved shareholder value[20] - Total assets amounted to CNY 1,185,934,827.59, a decrease of CNY 78,879,544.18 compared to the previous period[32] - Non-current liabilities increased to CNY 86,510,976.20, reflecting an increase of CNY 78,876,488.24 compared to the previous period[31] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥29,338,580.55, a decline of 56.46% compared to the same period last year[11] - Cash flow from operating activities for Q3 2021 was CNY 29,338,580.55, significantly lower than CNY 67,386,538.08 in Q3 2020, representing a decrease of 56.4%[26] - The company reported a net cash outflow from investing activities of CNY -20,230,488.44 in Q3 2021, compared to CNY -151,931,842.79 in Q3 2020[27] - The company’s total cash inflow from financing activities in Q3 2021 was CNY 444,566,892.67, compared to CNY 488,600,000.00 in Q3 2020, reflecting a decrease of 9.0%[27] - The cash and cash equivalents at the end of Q3 2021 were CNY 105,806,832.41, down from CNY 181,896,302.50 at the end of Q3 2020, a decline of 41.8%[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,778[12] - The largest shareholder, Cao Deli, holds 16.75% of the shares, amounting to 34,000,000 shares, with 25,500,000 shares pledged[12] - The second largest shareholder, Chen Xianyun, holds 8.22% of the shares, totaling 16,692,400 shares[12] - The third largest shareholder, Yang Yingli, holds 6.89% of the shares, amounting to 13,980,000 shares[12] - The company has not disclosed any other significant shareholder relationships beyond those mentioned[12] Research and Development - Research and development expenses increased by 69.48% to ¥16,878,871.98, reflecting higher investment in R&D materials[9] - Research and development expenses were reported at ¥16,878,871.98, up from ¥9,959,089.40, reflecting the company's commitment to innovation[21] Strategic Initiatives - The company is in the process of selling 100% equity of Zhejiang Yonghe Zhikong Technology Co., Ltd. to Zhiba Technology, which includes all rights to its subsidiaries[14] - The company is actively conducting audits and evaluations related to the asset sale, with board meetings planned to review the transaction[14] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[21] Stock Options - The stock option incentive plan has allowed 21 eligible participants to exercise 3.02 million options at a price of 14.19 RMB per share[15] - The company has a total of 934,750 stock options available for exercise under the incentive plan[15]

Financial Performance - The company's operating revenue for the first half of 2021 was approximately ¥424.57 million, representing a 39.55% increase compared to ¥304.24 million in the same period last year[19]. - The net profit attributable to shareholders of the listed company decreased by 13.81% to approximately ¥25.52 million, down from ¥29.60 million in the previous year[19]. - The net cash flow from operating activities fell by 49.62% to approximately ¥14.03 million, compared to ¥27.84 million in the same period last year[19]. - Total assets at the end of the reporting period increased by 12.42% to approximately ¥1.33 billion, up from ¥1.19 billion at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company increased by 5.44% to approximately ¥673.94 million, compared to ¥639.14 million at the end of the previous year[19]. - The basic earnings per share decreased by 13.33% to ¥0.13, down from ¥0.15 in the same period last year[19]. - The weighted average return on net assets decreased by 0.89 percentage points to 3.86% compared to 4.75% in the previous year[19]. - The total profit for the same period was 33.89 million CNY, which is a decrease of 13.30% compared to the previous year[36]. - The company's total revenue reached ¥424,568,719.79, representing a year-on-year increase of 33.47%[57]. - The gross profit margin for the industrial sector decreased by 3.73 percentage points to 28.60%[57]. - The total profit for the first half of 2021 was CNY 33,886,786.14, a slight decrease from CNY 39,086,510.64 in the same period of 2020[172]. Healthcare Sector Focus - The company is strategically entering the healthcare industry, focusing on precision radiation therapy for tumors, and plans to divest its fluid control business[27]. - The demand for cancer treatment in China is increasing, with new cancer cases expected to rise from approximately 4.4 million in 2019 to about 5.11 million by 2025[28]. - The company has established a platform for medical industry development through its wholly-owned subsidiary, Chengdu Yonghe Medical Technology Co., Ltd., focusing on tumor treatment services[30]. - The company has acquired Dazhou Medical Oncology Hospital and Kunming Medical Oncology Hospital, and has established a new hospital in Chongqing, expanding its network of specialized cancer treatment facilities[33]. - The company aims to enhance its operational capabilities in the healthcare sector by implementing refined management practices and establishing a comprehensive operational management system for its chain hospitals[38]. - The company is integrating advanced medical imaging and radiation therapy equipment in its hospitals to provide precise treatment for cancer patients[31]. - The radiation therapy adoption rate in China is significantly lower than in developed countries, indicating substantial growth potential in the market[29]. - The company has established a clear service positioning in the healthcare sector, targeting the growing demand for tumor precision radiotherapy amid an aging population and rising cancer incidence[42]. - The company has invested in multiple medical facilities, including Dazhou Medical Oncology Hospital and Kunming Medical Oncology Hospital, to strengthen its presence in the healthcare market[54]. Operational Risks and Management - The company faces various operational risks and has outlined corresponding countermeasures in its report[5]. - The company is actively restructuring its asset portfolio by divesting its traditional valve and pipe fittings business to focus on the healthcare sector, which is expected to enhance its capital for medical industry expansion[40]. - The company is addressing the risk of delayed medical insurance reimbursements by enhancing its brand reputation and reducing reliance on insurance payments[81]. - There is a risk of goodwill impairment due to acquisitions of hospitals, prompting the company to focus on improving operational and profitability metrics[82]. - The company is exposed to foreign exchange risks due to its reliance on exports, particularly in USD, and is implementing pricing mechanisms to mitigate this risk[83]. Investment and Financial Strategy - Research and development investment rose by 60.09% to approximately ¥9.53 million, compared to ¥5.96 million in the previous year, indicating a focus on enhancing R&D capabilities[52]. - The company plans to focus on the healthcare industry after exiting the fluid control business, which will optimize its capital structure and reduce financial costs[77]. - The company aims to enhance its sustainable development capabilities by investing the recovered funds into the healthcare industry[77]. - The company has implemented measures to avoid overdue accounts receivable and reduce customer default risks by purchasing credit insurance[74]. - The company has committed to a share buyback plan, with a target of acquiring between 1.9072 million and 2 million shares[112]. - The company applied for a total credit limit of up to RMB 600 million from banks to support development plans and strategic implementation[133]. Shareholder and Equity Information - The company did not distribute cash dividends or issue new shares in the first half of the year, maintaining its capital structure[88]. - The company has completed all commitments made by actual controllers, shareholders, and related parties during the reporting period[102]. - The company has fulfilled its commitment regarding the reduction of shareholding, allowing a maximum reduction of 5% of total shares within 24 months after the lock-up period[102]. - The company has ensured that any future compensation measures will be linked to the execution of relevant commitments[103]. - The company has not made any unfair conditions for other units or individuals that would harm the company's interests[103]. - The company has a total of 47,980,000 shares held by directors and supervisors at the beginning and end of the reporting period[151]. - The total number of common shareholders at the end of the reporting period was 15,251[148]. - The largest shareholder, Cao Deli, holds 17.00% of the shares, amounting to 34,000,000 shares, with 25,500,000 shares pledged[148]. - The company reported no changes in the number of shares held by directors and senior management during the reporting period[151]. Future Outlook and Strategic Initiatives - The company plans to continue focusing on market expansion and new product development to drive future growth[170]. - The company anticipates a gradual recovery in performance in the upcoming quarters, supported by strategic initiatives and market expansion efforts[190]. - The company aims to expand its market presence and enhance product development in the upcoming periods[197]. - The company is focusing on technological innovation and the development of new products to drive future growth[197]. - The company has plans for strategic investments and potential mergers to strengthen its market position[197].

Financial Performance - The company reported a total revenue of RMB 500 million for the year 2020, representing a year-on-year increase of 15%[12]. - The net profit attributable to shareholders was RMB 80 million, which is a 10% increase compared to the previous year[12]. - The company's operating revenue for 2020 was ¥647,691,188.74, representing a 9.40% increase compared to ¥592,058,026.89 in 2019[6]. - The net profit attributable to shareholders for 2020 was ¥12,924,662.58, a significant decrease of 78.53% from ¥60,199,518.00 in 2019[6]. - The total profit amounted to RMB 28.76 million, a decrease of 61.87% year-on-year[52]. - The net profit after deducting non-recurring gains and losses was ¥8,489,349.07, down 85.13% from ¥57,086,493.85 in 2019[6]. - The net cash flow from operating activities decreased by 23.24% to ¥56,472,415.67 from ¥73,571,356.00 in 2019[6]. - The total assets at the end of 2020 were ¥1,185,934,827.59, an increase of 56.77% from ¥756,494,685.39 at the end of 2019[6]. Strategic Plans and Investments - The company plans to invest RMB 50 million in research and development for new product lines in 2021[12]. - The management has set a revenue target of RMB 600 million for 2021, reflecting a growth rate of 20%[12]. - The company is focusing on the medical health industry, particularly in the field of precision radiation therapy for tumors, with plans to establish specialized hospitals in major cities[26]. - The company aims to enhance its industry foundation through investments and acquisitions, adopting a model of "internal growth + external mergers" to expand its market presence[27]. - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[12]. - The company has successfully acquired Dazhou Medical Oncology Hospital and Kunming Medical Oncology Hospital, and has established Chongqing Huapu Oncology Hospital, marking a strong start to its strategic transformation[33]. - The company aims to build a nationwide oncology medical service network, focusing on radiation therapy, to capture a larger market share in the growing sector[33]. Market Expansion and User Growth - User data indicates a growth in active users by 25%, reaching a total of 1 million users by the end of 2020[12]. - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 20% market share by 2023[12]. - The company has expanded its market presence in Southeast Asia, the Middle East, and South America, moving beyond its traditional markets in Europe and the US[55]. Risks and Challenges - The company has identified policy risks and goodwill impairment risks as significant factors affecting future performance[5]. - The aging population in China is leading to an increase in cancer incidence, with projections indicating that annual cancer cases will rise from approximately 4.4 million in 2019 to about 5.11 million by 2025[28]. - The company faces industry policy risks that may impact its ability to expand in the domestic market due to potential tightening of regulations on private medical investments[117]. - There is a risk of delayed reimbursement from local medical insurance, which could increase as the scale of hospital operations expands[118]. - The company is exposed to foreign exchange risks due to its reliance on exports, primarily settled in USD, and has implemented a pricing mechanism to mitigate this risk[121]. Research and Development - The company continues to focus on enhancing its intelligent control technology to improve product efficiency and customer satisfaction[12]. - The company has invested in Dazhou Medical Oncology Hospital, Kunming Medical Oncology Hospital, and holds shares in Xi'an Medical Oncology Hospital, focusing on precision radiation therapy[66]. - The company has implemented a multi-level incentive mechanism to attract and retain talent in the medical field, enhancing its operational capabilities[56]. - The company’s R&D expenses decreased by 24.35% to ¥14,058,334.55, representing 2.17% of operating revenue[73]. - The number of R&D personnel increased by 11.54% to 87, although the proportion of R&D personnel decreased to 8.42%[73]. Financial Management and Governance - The company raised a total of RMB 37,125.00 million from the public offering of 25 million shares at RMB 14.85 per share, with a net amount of RMB 32,821.27 million after deducting issuance costs of RMB 4,303.73 million[97]. - As of the end of the reporting period, the company had cumulatively used RMB 34,720.17 million of the raised funds, with RMB 2,936.15 million used during the reporting period[99]. - The company has no idle funds that have been unused for over two years[99]. - The company has committed to not occupying the funds or assets of the listed company and to minimize related party transactions, ensuring fairness and normal commercial conditions[133]. - The company has established a commitment to minimize related party transactions and ensure they are conducted under fair and reasonable commercial terms[138]. Compliance and Legal Matters - The company has not faced any major litigation or arbitration matters during the reporting period, reflecting a stable legal environment[156]. - The company has not experienced any penalties or rectification situations during the reporting period, indicating compliance with regulations[157]. - The company has not reported any non-compliance with commitments made regarding the waiver of voting rights[145]. Corporate Changes and Shareholder Commitments - The company changed its corporate type from "joint-stock company (Taiwan, Hong Kong, Macao and domestic joint venture, listed)" to "joint-stock company (listed)"[189]. - The controlling shareholder increased its stake by acquiring between 1.9 million and 2 million shares, representing approximately 0.9536% of the total share capital[190]. - The company plans to reduce its shareholding by no more than 25% of the total shares held during the 24 months following the expiration of the lock-up period[137]. - The company has completed its share reduction commitments as of the reporting period, with no shares held by certain stakeholders[138].

Financial Performance - The company's revenue for Q1 2021 was ¥180,406,859.36, representing a 37.77% increase compared to ¥130,945,135.99 in the same period last year[9] - Net profit attributable to shareholders was ¥7,390,662.30, a decrease of 4.97% from ¥7,777,412.59 in the previous year[9] - The net profit after deducting non-recurring gains and losses was ¥6,903,617.33, down 4.02% from ¥7,193,090.53 year-on-year[9] - Operating revenue for the current period reached ¥180,406,859.36, a 37.77% increase compared to ¥130,945,135.99 in the same period last year, driven by an expansion in business scale[19] - The company's total comprehensive income for the period was CNY -5,676,156.69, compared to CNY -883,593.19 in the previous period, indicating a decline in overall financial health[63] Cash Flow - The net cash flow from operating activities increased by 15.86% to ¥17,538,692.11 from ¥15,137,908.87 in the same period last year[9] - The net cash flow from operating activities was ¥17,538,692.11, a 15.86% increase from ¥15,137,908.87, mainly due to higher cash receipts from sales and tax refunds[21] - The net cash flow from investing activities improved by 88.21%, reducing losses to -¥8,339,974.85 from -¥70,721,066.18, as cash payments for investments decreased[21] - The net cash flow from operating activities for Q1 2021 was ¥976,804.13, a decrease of 74.7% compared to ¥3,859,275.63 in the same period last year[69] - Total cash inflow from operating activities was ¥3,451,170.74, down 85.3% from ¥23,605,367.67 in Q1 2020[69] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,258,335,756.56, up 6.10% from ¥1,185,934,827.59 at the end of the previous year[9] - The company's total assets as of March 31, 2021, were CNY 1,069,435,454.78, down from CNY 1,075,916,124.09 at the end of 2020[54] - The total liabilities increased to CNY 609,878,768.70 from CNY 544,960,214.46, representing an increase of approximately 11.9%[50] - Total liabilities increased to ¥544,960,214.46, reflecting a rise of ¥78,879,544.18 compared to the previous year[74] - The company's total equity remained stable at ¥640,974,613.13, unchanged from the previous year[74] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,068[12] - The company’s major shareholder, the actual controller, plans to increase holdings by acquiring between 1.9 million and 2 million shares, which has been completed with 1,907,200 shares acquired[22] - The company’s major shareholder transferred 58 million shares, representing 29.00% of total equity, to the actual controller, ensuring continued control over the company[25] Research and Development - R&D expenses surged by 86.92% to ¥4,091,776.07 from ¥2,189,109.63, indicating a significant increase in investment in research and development[19] - Research and development expenses for Q1 2021 were CNY 4,091,776.07, compared to CNY 2,189,109.63 in the previous period, indicating increased investment in innovation[57] Financial Management - Financial expenses skyrocketed by 356.41% to ¥8,058,672.53 from ¥1,765,667.35, primarily due to increased interest expenses on bank loans[19] - The company reported a significant credit impairment loss of CNY -1,230,736.95, which negatively impacted the overall profit[62] Investments and Loans - The company received a loan of RMB 28.5 million from its controlling shareholder, with a one-year term and no collateral required[32] - The company entered into a maximum loan agreement with its controlling shareholder for up to RMB 300 million, available for two years with a maximum loan term of 24 months[33] - The company engaged in derivative investments, including forward foreign exchange contracts with Bank of China and Industrial and Commercial Bank of China, with a total initial investment of RMB 195.82 million[38] Accounting and Standards - The company implemented a new leasing standard starting January 1, 2021, which resulted in adjustments to the financial statements[75] - The company has adopted the new leasing standards effective from January 1, 2021, impacting retained earnings and related financial statement items[77] - The first quarter report for 2021 has not been audited[78]

永和流体智控股份有限公司 2020 年第三季度报告全文 永和流体智控股份有限公司 2020 年第三季度报告 2020 年 10 月 1 永和流体智控股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曹德莅、主管会计工作负责人廖丽娜及会计机构负责人(会计主管人员)廖丽 娜声明：保证季度报告中财务报表的真实、准确、完整。 2 永和流体智控股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年 | | --- | --- | --- | --- | --- | | | | | | 度末增减 | | 总资产（元） | 1,121,751,747.77 | | 756,494,685.39 | 48.28% | | 归属于上市公司股东的净资产（元） ...

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 304,240,690.74, representing a 1.07% increase compared to CNY 301,015,681.21 in the same period last year[17]. - The net profit attributable to shareholders decreased by 22.31% to CNY 29,604,594.62 from CNY 38,106,430.13 year-on-year[17]. - The net cash flow from operating activities dropped significantly by 65.02%, amounting to CNY 27,843,865.47 compared to CNY 79,597,519.54 in the previous year[17]. - Basic earnings per share decreased by 21.05% to CNY 0.15 from CNY 0.19 in the same period last year[17]. - The weighted average return on net assets was 4.75%, down 0.56 percentage points from 5.31% in the previous year[17]. - The company reported a significant increase in management expenses by 70.02% to ¥31,345,928.50, primarily due to the expansion of its medical business[46]. - Research and development investment decreased by 35.99% to ¥5,955,045.63, reflecting a reduction in R&D activities[46]. - The company reported a financial expense of CNY 3,048,342.84, compared to a financial income of CNY 3,163,020.22 in the same period last year[169]. - The total profit for the first half of 2020 was CNY 39,086,510.64, down 14.7% from CNY 45,873,467.61 in the same period of 2019[171]. Assets and Liabilities - The total assets of the company increased by 38.83% to CNY 1,050,243,924.52 from CNY 756,494,685.39 at the end of the previous year[17]. - The total liabilities rose to CNY 410,256,288.00 from CNY 148,271,693.97, marking an increase of approximately 176.5%[163]. - Non-current assets increased to CNY 612,483,321.62 from CNY 257,232,227.79, a growth of about 138.5%[162]. - The company's equity attributable to shareholders rose to CNY 637,814,129.15 from CNY 608,222,991.42, an increase of approximately 4.8%[164]. - The total liabilities to equity ratio increased significantly, indicating a higher leverage position for the company[163]. Strategic Expansion - The company is expanding into the medical health industry, focusing on tumor precision radiation therapy and establishing specialized hospitals in key cities[25][26]. - The company has established a dual-industry strategy of "medical health industry + fluid control business" to enhance its comprehensive strength and profitability[25][32]. - The company has actively expanded into the medical health industry, acquiring Dazhou Medical Oncology Hospital and investing in Chongqing Huapu Oncology Hospital[40]. - The company aims to achieve chain and scale operations for oncology specialty hospitals in key domestic cities through both organic growth and acquisitions[40]. - The company is strategically transitioning towards the healthcare industry, focusing on precision radiation therapy for tumors, in response to complex international economic conditions and trade uncertainties[86]. Investment and Financing - The company plans to leverage capital market financing tools to enhance its financial strength and reduce operational liabilities[42]. - The company reported a net cash inflow from financing activities of ¥104,875,031.34, a 204.88% increase compared to the previous year[46]. - The company has short-term borrowings of ¥180 million, which is a new bank loan for working capital[53]. - The company plans to issue up to 60.36 million CNY in non-public shares at a price of 10.06 CNY per share to its actual controller, with proceeds used for repaying bank loans and supplementing working capital[114]. - The company applied for a comprehensive credit facility totaling up to RMB 600 million to support its development plans and strategic implementation[127]. Risk Management - The company has established a risk management system for foreign exchange hedging, which prohibits speculative and arbitrage trading[70]. - The company plans to actively manage accounts receivable to prevent overdue payments and reduce risks associated with customer defaults[70]. - The company emphasizes the importance of aligning delivery periods with business cycles in its forward foreign exchange transactions[70]. - The cost of copper rods accounts for approximately 60% of the production costs, making copper price fluctuations a significant risk for the company[90]. - The company exports over 90% of its valve and pipe products, primarily priced in USD, exposing it to RMB exchange rate risks[91]. Corporate Governance - The financial report was approved by the board of directors on August 24, 2020, ensuring governance compliance[199]. - The company has not faced any penalties or rectification issues during the reporting period[106]. - The company has fulfilled its commitments regarding shareholding and voting rights[101]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[145]. - The company appointed a new financial director, Liao Lina, on August 24, 2020, following the resignation of the previous financial director[154]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,172[142]. - The largest shareholder, Taizhou Yongjian Holdings Co., Ltd., holds 29.00% of the shares, totaling 58,000,000 shares, which are pledged[142]. - The company has a commitment to reduce stock holdings by no more than 5% of total shares each year after the lock-up period[96]. - The unrestricted shares decreased by 22,458,000 shares, resulting in 177,542,000 unrestricted shares, which is 88.77% of total shares[138]. - The company has a commitment to not reduce its shareholding by more than 25% of total shares during the lock-up period[99]. Compliance and Reporting - The financial report for the half-year period has not been audited[159]. - There were no major litigation or arbitration matters during the reporting period[104]. - The company has not reported any significant environmental violations or penalties during the reporting period[123]. - The company has not initiated any poverty alleviation programs or plans for the reporting year[125]. - The company has not engaged in any related party transactions during the reporting period, including asset or equity acquisitions[110][111][112][113].

Financial Performance - Revenue for Q1 2020 was CNY 130,945,135.99, a decrease of 4.65% compared to CNY 137,327,723.12 in the same period last year[7] - Net profit attributable to shareholders was CNY 7,777,412.59, down 47.15% from CNY 14,714,968.63 year-on-year[7] - Basic and diluted earnings per share were both CNY 0.0389, reflecting a 47.15% decline from CNY 0.0736 in the same quarter last year[7] - The company reported a total comprehensive income of CNY 7,621,261.78, compared to CNY 14,639,718.94 in the same period last year[49] - Operating profit for the first quarter was CNY 11,908,204.32, down 33.5% from CNY 17,935,755.24 in the previous period[48] - The company reported a 66.03% decline in investment income to ¥574,263.17, mainly due to reduced bank wealth management products[16] - The company incurred a financial expense of CNY 1,765,667.35, slightly up from CNY 1,738,943.99[48] - The tax expense for the quarter was CNY 4,127,024.22, an increase from CNY 3,161,727.38 year-over-year[48] Cash Flow - Net cash flow from operating activities decreased by 64.54%, amounting to CNY 15,137,908.87 compared to CNY 42,686,856.38 in the previous year[7] - Cash inflow from operating activities was CNY 182,382,730.79, down from CNY 193,430,741.47 in the previous period[54] - The total cash outflow from operating activities was ¥167,244,821.92, compared to ¥150,743,885.09 in the previous year, indicating an increase of 10.5%[56] - The net cash flow from investing activities was -¥70,721,066.18, a significant decline from -¥17,367,739.98 year-over-year[56] - Cash and cash equivalents at the end of the period were ¥88,611,922.80, down from ¥97,367,844.38 at the end of the previous year[57] - The company experienced a net increase in cash and cash equivalents of -¥20,583,991.36 during the quarter, compared to -¥7,206,468.74 in the previous year[57] Assets and Liabilities - Total assets increased by 4.85% to CNY 793,193,826.04 from CNY 756,494,685.39 at the end of the previous year[7] - Current liabilities increased to CNY 164,407,476.16 from CNY 137,853,778.47, reflecting a rise of 19.2%[40] - The company’s total liabilities amounted to CNY 175,155,271.75, compared to CNY 148,271,693.97, which is an increase of 18.1%[40] - Total current assets decreased from ¥499,262,457.60 at the end of 2019 to ¥386,094,467.89, reflecting a reduction of about 22.6%[38] - The company’s total equity attributable to shareholders reached CNY 608,222,991.42, with retained earnings of CNY 115,728,694.71[68] Shareholder Information - The total number of shareholders at the end of the reporting period was 17,521[11] - The largest shareholder, Taizhou Yongjian Holding Co., Ltd., held 29.00% of the shares, amounting to 58,000,000 shares[11] Investments and Acquisitions - The company completed the acquisition of 95% equity in Dazhou Zhongke for ¥88.6 million, which will be consolidated into the financial statements[21] - The company also acquired 100% equity in Chengdu Shanshuishang Hotel for ¥126 million, which will be included in the consolidated financial statements[23] - The company completed the acquisition of 95% equity in Dazhou Zhongke Oncology Hospital Co., Ltd. on January 20, 2020[25] - The company announced the acquisition of 100% equity in Chengdu Shanshui Shang Hotel Co., Ltd. on April 2, 2020[25] Expenses - Management expenses increased by 38.48% to ¥14,397,469.35 due to new investments in the healthcare industry[16] - Research and development expenses decreased by 46.13% to ¥2,189,109.63, primarily due to reduced investment during the pandemic[16] Other Financial Information - Non-recurring gains and losses totaled CNY 584,322.06, primarily from government subsidies and investment income[8] - The company has ongoing projects in construction valued at CNY 54,177,621.74, down from CNY 60,674,830.00, indicating a decrease of 8.2%[41] - The company has a total of 1,300 million yuan in bank wealth management products, with a 3.00% annualized return[29] - The company has not reported any significant or low-security, illiquid, or non-principal-protected high-risk entrusted financial management situations[29] - The company has not disclosed any derivative investments during the reporting period[30]

Financial Performance - The company's operating revenue for 2019 was approximately ¥592.06 million, a decrease of 8.12% compared to ¥644.37 million in 2018[15] - The net profit attributable to shareholders for 2019 was approximately ¥60.20 million, down 25.98% from ¥81.33 million in 2018[15] - The net cash flow from operating activities decreased by 39.01% to approximately ¥73.57 million in 2019, compared to ¥120.62 million in 2018[15] - Basic earnings per share for 2019 were ¥0.30, a decline of 26.83% from ¥0.41 in 2018[15] - The total assets at the end of 2019 were approximately ¥756.49 million, a slight decrease of 0.19% from ¥757.90 million at the end of 2018[15] - The net assets attributable to shareholders decreased by 6.13% to approximately ¥608.22 million at the end of 2019, down from ¥647.97 million at the end of 2018[15] - The weighted average return on equity for 2019 was 9.98%, down from 12.95% in 2018, a decrease of 2.97 percentage points[15] - The company reported a decrease in net profit after deducting non-recurring gains and losses, which was approximately ¥57.09 million in 2019, down 34.90% from ¥87.70 million in 2018[15] - Total revenue for the year was 592,058,027.89 CNY, with a quarterly breakdown of 137,327,723.12 CNY in Q1, 163,687,958.09 CNY in Q2, 153,516,127.86 CNY in Q3, and 137,526,217.82 CNY in Q4[19] - Net profit attributable to shareholders for the year was 60,698,518.00 CNY, with quarterly figures of 14,714,968.63 CNY in Q1, 23,391,461.50 CNY in Q2, 18,850,455.50 CNY in Q3, and 3,242,632.37 CNY in Q4[19] - The net cash flow from operating activities was 73,571,355.00 CNY for the year, with negative cash flow in Q3 and Q4 of -2,222,064.50 CNY and -3,804,099.04 CNY respectively[19] - The total revenue for 2019 was CNY 592.06 million, a decrease of CNY 5.23 million or 8.12% compared to the previous year[48] - The net profit attributable to shareholders was CNY 60.20 million, down CNY 2.11 million or 25.98% year-on-year[48] - Sales expenses and management expenses increased by CNY 18.33 million compared to the previous year, impacting profit margins[48] Market and Strategic Focus - The company continues to focus on the production of lead-free brass valves and fittings, which aligns with industry trends towards environmental sustainability[31] - The company is actively exploring new markets in South America and Southeast Asia to expand its customer base and develop its own brand[28] - The global demand for plumbing and heating equipment is expected to grow, driven by urbanization and infrastructure investment in emerging markets[30] - The company maintains strategic partnerships with major international brands such as HONEYWELL and WATTS, primarily operating under ODM and OEM models[28] - The company has established a competitive advantage in the domestic market due to its location in Zhejiang Yuhuan, a major manufacturing hub for plumbing products[32] - The company is actively exploring emerging markets in Southeast Asia, the Middle East, and South America to drive future growth[49] - The company plans to expand into new markets, particularly in emerging markets like Russia, to drive sustainable growth[92] - The company aims to enhance its production efficiency through technology upgrades and automation, targeting to become a preferred supplier in the global water and HVAC sectors[92] Investment and Subsidiaries - The company established a wholly-owned subsidiary, Chengdu Yonghe Cheng Medical Technology Co., Ltd., to expand into the healthcare industry[49] - The company established two new subsidiaries in November 2019, expanding its operational footprint[58] - The company established three new subsidiaries in 2019: Chengdu Yonghe Cheng Medical Technology Co., Ltd., Zhejiang Yonghe Zhikong Technology Co., Ltd., and Xiamen Yonghe Medical Oncology Hospital Co., Ltd.[138] - The company completed the acquisition of 95% of Dazhou Zhongke Tumor Hospital Co., Ltd. for RMB 88.6 million, integrating it into the company's operations[176] - Chengdu Yonghe Cheng invested RMB 25.5 million for a 51% stake in Xiamen Yonghe Medical Oncology Hospital Co., Ltd., expanding its healthcare services[175] Risks and Challenges - The company has indicated various risk factors affecting its operations, including raw material price fluctuations and policy risks[5] - The company faces risks from raw material price fluctuations, particularly copper, which constitutes about 60% of production costs[97] - The company is exposed to foreign exchange risks due to 90% of its sales being in USD, and it has mechanisms in place to mitigate these risks[98] - The company reported a significant decline in sales revenue in the U.S. market due to the impact of the U.S.-China trade war, alongside a downturn in the European economy[86] Cash Dividend Policy - The company does not plan to distribute cash dividends or issue bonus shares for the year[5] - The company proposed not to distribute cash dividends for the fiscal year 2019, nor to issue bonus shares or increase capital from reserves[107] - The cash dividend distribution plan for 2019 is subject to approval at the annual shareholders' meeting[107] - The retained earnings will be carried forward for future distribution, with a commitment to prioritize cash dividends for investors[110] - The company has established a transparent decision-making process for its cash dividend policy, ensuring protection of minority shareholders' rights[106] - The company has committed to avoiding related party transactions that could harm the interests of shareholders[114] Governance and Compliance - The company has not reported any significant discrepancies between financial reports prepared under international accounting standards and those under Chinese accounting standards[17] - The company has not made any adjustments to its cash dividend policy during the reporting period[106] - The company has committed to maintaining a prudent approach to its compensation system and any proposed equity incentive conditions[123] - The company will ensure compliance with regulatory requirements regarding compensation measures and will issue supplementary commitments if necessary[123] - The company has implemented measures to stabilize its stock price through potential share repurchases and management purchases[124] Financial Management - The company has significant restricted assets totaling 22,468,993.59, including cash, fixed assets, and intangible assets[71] - The company’s cash flow remains stable and secure, supported by timely and stable sales returns from quality foreign trade clients[45] - The company’s financial assets at fair value increased significantly, with initial investment costs of 175,067,315.25 and a total of 632,067,315.25 at the end of the period[76] - The company has no significant guarantees during the reporting period[154] - The company has no intention of engaging in similar business activities as Yonghe Shares, ensuring no competition and prioritizing Yonghe Shares in investment opportunities[121] Shareholder Structure - The controlling shareholder, Taizhou Yongjian Holdings Co., Ltd., underwent a division, reducing its stake in the company from 38.25% to 29%[165] - The actual controller of the company is Cao Deli, who has been the chairman since the change of control on November 7, 2019[192] - The largest shareholder, Taizhou Yongjian Holdings Co., Ltd., holds 29.00% of the shares, totaling 58,000,000 shares, with a decrease of 18,497,600 shares during the reporting period[189] - The company has a total of 21,495 shareholders, with 18,453 being common stockholders[189] - There are no other shareholders holding more than 10% of the shares, indicating a concentrated ownership structure[193]

Financial Performance - Operating revenue for the reporting period was CNY 153,516,127.86, down 14.20% year-on-year [7]. - Net profit attributable to shareholders was CNY 18,850,455.50, a decline of 34.78% compared to the same period last year [7]. - Basic earnings per share were CNY 0.0943, reflecting a decrease of 34.74% year-on-year [7]. - The company experienced a decrease in net profit margin, with a net profit margin of approximately 12.27% for the reporting period [7]. - The company's net profit for the period was CNY 28,057,063.04, reflecting a significant decline from CNY 40,365,929.25 in the previous year [53]. - The net profit for the third quarter was CNY 18,850,455.50, down 34.8% from CNY 28,901,921.72 year-over-year [55]. - The total profit for the third quarter was CNY 23,850,303.71, a decrease of 34.0% from CNY 36,151,709.28 in the previous year [54]. - The total profit for Q3 2019 was CNY 69,723,771.32, compared to CNY 74,920,605.50 in the previous year, showing a decrease of about 6.5% [62]. Cash Flow - The net cash flow from operating activities was negative CNY 2,222,064.50, a decrease of 102.88% compared to the same period last year [7]. - Operating cash flow net amount decreased by 29.98% to ¥77,375,455.04 due to a decline in main business revenue [16]. - The net cash flow from operating activities for Q3 2019 was ¥77,375,455.04, a decrease of 30% compared to ¥110,511,027.85 in Q3 2018 [70]. - The total cash inflow from investment activities was ¥526,334,126.34, down from ¥672,233,583.58 in the previous year, reflecting a decline of approximately 22% [71]. - The net cash flow from financing activities was -¥100,000,000.00, compared to -¥51,942,471.42 in Q3 2018, indicating a worsening of 92% [71]. - The cash flow from investment activities generated a net inflow of ¥22,380,140.75, contrasting with a net outflow of -¥50,977,856.68 in Q3 2018 [71]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 703,669,078.35, a decrease of 7.16% compared to the end of the previous year [7]. - The company's current assets totaled ¥495,205,008.17, down from ¥566,349,755.05 in the previous year [44]. - Total liabilities decreased to CNY 98,638,152.60 from CNY 109,935,457.86, a reduction of 10.2% [46]. - The company's equity attributable to shareholders decreased to CNY 605,030,925.75 from CNY 647,967,559.61, a decline of 6.6% [46]. - Inventory levels were reported at ¥120,701,429.76, down from ¥151,822,746.52 [43]. - Non-current assets increased to ¥208,464,070.18 from ¥191,553,262.42 [44]. Shareholder Information - The company reported a total of 20,416 common shareholders at the end of the reporting period [11]. - The largest shareholder, Taizhou Yongjian Holding Co., Ltd., held 29.00% of the shares, amounting to 58,000,000 shares [11]. - The controlling shareholder completed a division of shares, transferring 9.25% to a newly established company, maintaining a 29% stake [17]. - Senior management has committed to limit annual stock transfers to no more than 25% of their total holdings during their tenure [32]. Commitments and Plans - The company committed to not occupying its funds through various means, including lending to itself or related parties [29]. - The company has no plans to engage in any business similar to that of Yonghe Co., ensuring no competition with its own interests [29]. - The company plans to notify the market three trading days in advance of any stock reduction activities [31]. - The company has established a long-term commitment to fulfill its obligations regarding social security and housing fund contributions [28]. - The company has confirmed that all commitments made are being fulfilled on time [28]. Investment and Expenses - Research and development expenses for the quarter were CNY 3,594,895.73, down from CNY 4,243,399.86, a decrease of 15.4% [53]. - Research and development expenses for the third quarter were CNY 3,400,300.08, a decrease of 14.1% from CNY 3,959,970.10 in the same period last year [57]. - The company reported a significant increase in other income to CNY 493,403.95 from CNY 807,516.28, indicating a decrease of 38.8% year-over-year [53]. - The company reported a decline in investment income, resulting in a loss of ¥2,826,244.95 [15].